Navegar

Colección

Datos Estadísticas

Artículo

Guillon, J.; Le Borgne, M.; Rimbault, C.; Moreau, S.; Savrimoutou, S.; Pinaud, N.; Baratin, S.; Marchivie, M.; Roche, S.; Bollacke, A.; Pecci, A.; Alvarez, L.; Desplat, V.; Jose, J. "Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2" (2013) European Journal of Medicinal Chemistry. 65:205-222
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

Herein we describe the synthesis and properties of substituted phenylaminopyrrolo[1,2-a]quinoxaline-carboxylic acid derivatives as a novel class of potent inhibitors of the human protein kinase CK2. A set of 15 compounds was designed and synthesized using convenient and straightforward synthesis protocols. The compounds were tested for inhibition of human protein kinase CK2, which is a potential drug target for many diseases including inflammatory disorders and cancer. New inhibitors with IC 50 in the micro- and sub-micromolar range were identified. The most promising compound, the 4-[(3-chlorophenyl) amino]pyrrolo[1,2-a]quinoxaline-3-carboxylic acid 1c inhibited human CK2 with an IC 50 of 49 nM. Our findings indicate that pyrrolo[1,2-a]quinoxalines are a promising starting scaffold for further development and optimization of human protein kinase CK2 inhibitors. © 2013 Elsevier Masson SAS. All rights reserved.

Registro:

Documento: Artículo
Título:Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2
Autor:Guillon, J.; Le Borgne, M.; Rimbault, C.; Moreau, S.; Savrimoutou, S.; Pinaud, N.; Baratin, S.; Marchivie, M.; Roche, S.; Bollacke, A.; Pecci, A.; Alvarez, L.; Desplat, V.; Jose, J.
Filiación:Université Bordeaux Segalen, Pharmacochimie, FRE 3396, F-33000 Bordeaux, France
CNRS, Pharmacochimie, FRE 3396, F-33000 Bordeaux, France
Université de Lyon, Faculté de Pharmacie, SFR Santé Lyon-Est CNRS UMS3453 - INSERM US7, 8 avenue Rockefeller, F-69373 Lyon Cedex 8, France
ISM, CNRS UMR 5255, Université de Bordeaux, 351 cours de la Libération, F-33405 Talence cedex, France
Institut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität Münster, Hittorfstraße 58-62, 48149 Münster, Germany
Departamento de Química Biológica and IFIBYNE (CONICET-UBA), Facultad de Ciencias Exactas Y Naturales, Universidad de Buenos Aires, C1428EGA Buenos Aires, Argentina
Departamento de Química Orgánica and UMYMFOR (CONICET-UBA), Facultad de Ciencias Exactas Y Naturales, Universidad de Buenos Aires, C1428EGA Ciudad de Buenos Aires, Argentina
Palabras clave:Antiproliferative activity; Protein kinase CK2; Pyrrolo[1,2-a]quinoxaline; Synthesis; carboxylic acid derivative; casein kinase II; quinoxaline derivative; antiproliferative activity; article; cell strain K 562; controlled study; drug screening; drug synthesis; human; human cell; IC 50; in vitro study; leukemia cell; molecular dynamics
Año:2013
Volumen:65
Página de inicio:205
Página de fin:222
DOI: http://dx.doi.org/10.1016/j.ejmech.2013.04.051
Título revista:European Journal of Medicinal Chemistry
Título revista abreviado:Eur. J. Med. Chem.
ISSN:02235234
CODEN:EJMCA
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_02235234_v65_n_p205_Guillon

Referencias:

  • Chen, J.M., Gao, C., Shi, Q., Shan, B., Lei, Y.J., Dong, C.F., An, R., Dong, X.P., (2008) Arch. Virol., 153, pp. 1013-1020
  • Burnett, G., Kennedy, E.P., (1954) J. Biol. Chem., 211, pp. 969-980
  • Ahmed, K., Issinger, O.G., Niefind, K., (2011) Mol. Cell. Biochem., 356, pp. 1-3
  • Piazza, F., Manni, S., Ruzzene, M., Pinna, L.A., Gurrieri, C., Semenzato, G., (2012) Leukemia, 26, pp. 1174-1179
  • Lolli, G., Pinna, L.A., Battistutta, R., (2012) Chem. Biol., 7, pp. 1158-1163
  • Bliesath, J., Huser, N., Omori, M., Bunag, D., Proffitt, C., Streiner, N., Ho, C., Drygin, D., (2012) Cancer Lett., 322, pp. 113-118
  • Zheng, Y., Qin, H., Frank, S.J., Deng, L., Litchfield, D.W., Tefferi, A., Pardanani, A., Benveniste, E.N., (2011) Blood, 118, pp. 156-166
  • Papinutto, E., Ranchio, A., Lolli, G., Pinna, L.A., Battistutta, R., (2012) J. Struct. Biol., 177, pp. 382-391
  • Trembley, J.H., Chen, Z., Unger, G., Slaton, J., Kren, B.T., Van, W.C., Ahmed, K., (2010) Biofactors, 36, pp. 187-195
  • Prudent, R., Cochet, C., (2009) Chem. Biol., 16, pp. 112-120
  • Sarno, S., Papinutto, E., Franchin, C., Bain, J., Elliott, M., Meggio, F., Kazimierczuk, Z., Pinna, L.A., (2011) Curr. Top. Med. Chem., 11, pp. 1340-1351
  • Kim, J., Kim, S.H., (2012) Arch. Pharm. Res., 35, pp. 1293-1296
  • Campiani, G., Butini, S., Fattorusso, C., Trotta, F., Franceschina, S., De Angelis, M., Nielsen, K.S., (2006), PCT WO2006072608; Campiani, G., Aiello, F., Fabbrini, M., Morelli, E., Ramunno, A., Armaroli, S., Nacci, V., Caccia, S., (2001) J. Med. Chem., 44, pp. 305-315
  • Schann, S., Mayer, S., Gardan, S., (2007), Eur. Patent EP1798233; Guillon, J., Grellier, P., Labaied, M., Sonnet, P., Léger, J.-M., Déprez-Poulain, R., Forfar-Bares, I., Jarry, C., (2004) J. Med. Chem., 47, pp. 1997-2009
  • Guillon, J., Forfar, I., Mamani-Matsuda, M., Desplat, V., Saliège, M., Thiolat, D., Massip, S., Mossalayi, D., (2007) Bioorg. Med. Chem., 15, pp. 194-210
  • Guillon, J., Forfar, I., Desplat, V., Belisle-Fabre, S., Thiolat, D., Massip, S., Carrie, H., Jarry, C., (2007) J. Enzyme Inhib. Med. Chem., 22, pp. 541-549
  • Guillon, J., Moreau, S., Mouray, E., Sinou, V., Forfar, I., Belisle-Fabre, S., Desplat, V., Grellier, P., (2008) Bioorg. Med. Chem., 16, pp. 9133-9144
  • Guillon, J., Mouray, E., Moreau, S., Mullié, C., Forfar, I., Desplat, V., Belisle-Fabre, S., Grellier, P., (2011) Eur. J. Med. Chem., 46, pp. 2310-2326
  • Milne, J., Normington, K.D., Milburn, M., (2006), PCT WO2006094210; Grande, F., Aiello, F., De Grazia, O., Brizzi, A., Garofalo, A., Meamati, N., (2007) Bioorg. Med. Chem., 15, pp. 288-294
  • Desplat, V., Geneste, A., Begorre, M.-A., Belisle Fabre, S., Brajot, S., Massip, S., Thiolat, D., Guillon, J., (2008) J. Enzyme Inhib. Med. Chem., 23, pp. 648-658
  • Desplat, V., Moreau, S., Gay, A., Belisle-Fabre, S., Thiolat, D., Massip, S., Mossalayi, D., Guillon, J., (2010) J. Enzyme Inhib. Med. Chem., 25, pp. 204-215
  • Desplat, V., Moreau, S., Belisle-Fabre, S., Thiolat, D., Uranga, J., Lucas, R., Massip, S., Guillon, J., (2011) J. Enzyme Inhib. Med. Chem., 26, pp. 657-667
  • Röder, E., Wiedenfeld, H., Bourauel, T., (1987) Liebigs Ann. Chem., 12, pp. 1117-1119
  • Zhou, Z.-L., Kher, S.M., Cai, S.X., Whittemore, E.R., Espitia, S.A., Hawkinson, J.E., Tran, M., Keana, J.F.W., (2003) Bioorg. Med. Chem., 11, pp. 1769-1780
  • Guandalini, L., Martini, E., Romanelli, M.N., Dallatomasina, F., (2008), PCT WO2008012852A1; Guillon, J., Alsaidi, A., Dallemagne, P., Rault, S., (1998) Pharm. Pharmacol. Commun., 4, pp. 231-235
  • Yoo, S., Lee, S., (1990) Synlett, 7, pp. 419-420
  • Alleca, S., Corona, P., Loriga, M., Paglietti, G., Loddo, R., Mascia, V., Busonera, B., La Colla, P., (2003) Farmaco, 58, pp. 639-650
  • Ahman, J., Buchwald, S.L., (1997) Tetrahedron Lett., 38, pp. 6363-6366
  • Supplementary X-ray Crystallographic Data, , Cambridge Crystallographic Data Centre, University Chemical Lab, Lensfield Road, Cambridge, CB2 1EW, UK; E-mail: deposit@chemcrys.cam.ac.uk
  • McFarland, C., Vicic, D.A., Debnath, A.K., (2006) Synthesis, 5, pp. 807-812
  • Lalonde, J.M., Elban, M.A., Courter, J.R., Sugawara, A., Soeta, T., Madani, N., Princiotto, A.M., Smith III, A.B., (2011) Bioorg. Med. Chem., 19, pp. 91-101
  • Guillon, J., Reynolds, R., Léger, J.-M., Guié, M.-A., Massip, S., Dallemagne, P., Jarry, C., (2004) J. Enzyme Inhib. Med. Chem., 19, pp. 489-495
  • Lavastre, O., Cabioch, S., Dixneuf, P.H., Vohlidal, J., (1997) Tetrahedron, 53, pp. 7595-7604
  • Erdélyi, M., Gogoll, A., (2001) J. Org. Chem., 66, pp. 4165-4169
  • Galambos, G., Csokasi, P., Szantay Jr., C., Szantay, C., (1997) Liebigs Ann./Recueil, pp. 1969-1978
  • Liu, L.T., Yuan, T.-T., Liu, H.-H., Chen, S.-F., Wu, Y.-T., (2007) Bioorg. Med. Chem. Lett., 17, pp. 6373-6377
  • Ermakova, I., Boldyreff, B., Issinger, O.G., Niefind, K., (2003) J. Mol. Biol., 330, pp. 925-934
  • Gratz, A., Götz, C., Jose, J., (2010) Electrophoresis, 31, pp. 634-640
  • Hundsdörfer, C., Hemmerling, H.-J., Götz, C., Totzke, F., Bednarski, P., Le Borgne, M., Jose, J., (2012) Bioorg. Med. Chem., 20, pp. 2282-2289
  • http://www.molinspiration.com/cgi-bin/properties, accessed 20.03.13; Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., (2001) Adv. Drug Del. Rev., 46, pp. 3-26
  • Clark, D.E., (1999) J. Pharm. Sci., 88, pp. 807-814
  • Ertl, P., Rohde, B., Selzer, P., (2000) J. Med. Chem., 43, pp. 3714-3717
  • Battistutta, R., Cozza, G., Pierre, F., Papinutto, E., Lolli, G., Sarno, S., O'Brien, S.E., Pinna, L.A., (2011) Biochemistry, 50, pp. 8478-8488
  • Liu, H., Wang, X., Wang, J., Wang, J., Li, Y., Yang, L., Li, G., (2011) Int. J. Mol. Sci., 12, pp. 7004-7021
  • North, A.C.T., Phillips, D.C., Mathews, F.S., (1968) Acta Crystallogr., A24, p. 351
  • Sheldrick, G.M., Kröger, C., Goddard, R., (1985) SHELX 86 in Crystallographic Computing 3, p. 175. , Oxford University Press, New-York
  • Sheldrick, G.M., (1993) SHELX 93, Program for the Refinement of the Crystal Structures, , University of Göttingen, Germany
  • Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Montgomery Jr., J.A., Pople, J.A., (2004) Gaussian 03, , Revision C.02, Gaussian, Inc., Wallingford CT
  • Pearlman, D.A., Case, D., Caldwell, J.W., Ross, W.S., Cheatham III, T.E., DeBolt, S., Ferguson, D., Kollman, P., (1995) Comput. Phys. Commun., 91, pp. 1-41
  • Berendsen, H.J.C., Postma, J.P.M., Van Gunsteren, W.F., DiNola, A., Haak, J.R., (1984) J. Chem. Phys., 81, pp. 3684-3690
  • Cheatham III, T.E., Cieplak, P., Kollman, P.A., (1999) J. Biomol. Struct. Dynam., 16, pp. 845-862

Citas:

---------- APA ----------
Guillon, J., Le Borgne, M., Rimbault, C., Moreau, S., Savrimoutou, S., Pinaud, N., Baratin, S.,..., Jose, J. (2013) . Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2. European Journal of Medicinal Chemistry, 65, 205-222.
http://dx.doi.org/10.1016/j.ejmech.2013.04.051
---------- CHICAGO ----------
Guillon, J., Le Borgne, M., Rimbault, C., Moreau, S., Savrimoutou, S., Pinaud, N., et al. "Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2" . European Journal of Medicinal Chemistry 65 (2013) : 205-222.
http://dx.doi.org/10.1016/j.ejmech.2013.04.051
---------- MLA ----------
Guillon, J., Le Borgne, M., Rimbault, C., Moreau, S., Savrimoutou, S., Pinaud, N., et al. "Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2" . European Journal of Medicinal Chemistry, vol. 65, 2013, pp. 205-222.
http://dx.doi.org/10.1016/j.ejmech.2013.04.051
---------- VANCOUVER ----------
Guillon, J., Le Borgne, M., Rimbault, C., Moreau, S., Savrimoutou, S., Pinaud, N., et al. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2. Eur. J. Med. Chem. 2013;65:205-222.
http://dx.doi.org/10.1016/j.ejmech.2013.04.051